The Life Sciences sector includes companies involved in biopharmaceuticals, medical manufacturing and distribution, and bio products.
The issuer is a science and technology health and wellness company that encompasses plant based, psychedelic pharmaceutical and non-psychedelic nutraceutical, and hemp cannabinoids (CBD) verticals.
CannAmerica Brands Corp. is a U.S. marine veteran founded and operated portfolio of cannabis brands with licensing agreements in the states of Colorado, Nevada and Maryland. CannAmerica aims to maximize the value of its brands by employing strong brand management teams, marketing and licensing the brands through various distribution channels, including dispensaries, wholesalers and distributors, in the United States and internationally.
Canntab Therapeutics Limited is a Canadian cannabis oral dosage formulation company based in Markham Ontario, engaged in the research and development of advanced pharmaceutical grade formulations of cannabinoids. Canntab has developed in-house technology to deliver standardized medical cannabis extract from selective strains in a variety of extended/sustained release pharmaceutical dosages for therapeutic use. Simply put, Canntab's mission is to put the "Medical" into medicinal cannabis.
Cansortium Inc. is a medical cannabis company operating in highly populous medical cannabis markets with a mission to deliver the highest standards of cannabis care from nursery to lab to shelf. Headquartered in Miami, FL and operating under the Fluent™ Cannabis Care brand, the Company operates in Florida, Texas and Pennsylvania, and has partnered with a license-holder in Michigan. For more information please visit www.getfluent.com.
Investor Note: In addition to the 113,803,920 Common Shares that are listed and trading, there are 7,411,183 Proportionate Voting Shares, convertible into Common Shares at a ratio of 1:10, that are issued and outstanding but not listed. The total number of issued shares, assuming all are converted into the listed class, would be 187,915,750.
The Exchange has determined that the Issuer has not met the continued listing requirements as set out in CSE Policy 2, Appendix A, section 2.9.
Pursuant to Policy 6 section 2.4, the Issuer may not rely on confidential price protection, nor may the Issuer complete a financing without prior Exchange approval.
In accordance with Policy 3, section 5.1, the .X extension is added to the listed securities of Issuers that the Exchange has deemed to be inactive.
CBD Global Sciences, Inc., is a hemp-based CBD producer and branding investment vehicle which currently owns two brands, branded under the name Aethics™ (www.aethics.com) and CANNAOIL (www.cannaoilshop.com), which include CBD Oil tinctures (liquid products), CBD capsules, CBD topicals, Hydration products and Confectionary products. CBD Global Sciences hemp-derived CBD extracts are sold through select distributors, brick and mortar retailers, and online. CBD Global Sciences, through its wholly owned subsidiaries, Global Sciences Holdings, Resinosa LLC (www.resinosa.com) and Legacy Distribution Group, (www.legacydistributiongroup.com ), is delivering quality CBD products both in a retail and e-commerce formats nationwide. The Direct Store Delivery (DSD) provides distribution services for multiple vendors of CBD infused products and non-CBD products throughout the Colorado and Wyoming territories that are currently servicing over 750 C-store and large box retailers with expansion plans to exceed 5,000 stores in the next 12-24 months. In addition to Legacy Distribution it has added a manufacturing division, Resinosa LLC (www.Resinosa.com ), with its capabilities to provide cGMP manufacturing to the CBD industry with both private label and white label CBD and non-CBD product lines.
.
The business of the Issuer is the development of non-alcoholic beverages and the generation of retail sales.
Chemesis International Inc. is a U.S. focused multi-state cannabis company, that is focused on providing an artificially intelligent (AI) based retail solution. The Company currently holds exclusive rights to an AI based kiosk which can be deployed in high traffic areas such as, shopping malls, stadiums, transit hubs, workplaces, and large corporate headquarters.
Chemesis and its team are committed to building a strong unattended and attended retail model for the cannabis market across the United States. Chemesis’ retail brand, Green Spirit Rx, will continue to provide consumers with industry-leading technology, the most sought-after products and education.
Choom Holdings Inc., an adult use cannabis company, is currently developing one of the largest cannabis retail networks across Canada. Choom is focused on delivering an elevated customer experience through its curated retail environments, offering a diversity of brands for Canadians across a national retail network.
Advertisement
Publicité
Advertisement
Publicité
